Ryota Tanaka - Concepedia

Author

Ryota Tanaka

Also Known As

R Tanaka, R. Accinelli Tanaka, R. Tanaka, RYOTA TANAKA, Risa Tanaka, Ryota TANAKA, Ryota Tanaka, S. Matsushita, Shigeto Matsushita, Tanaka, Ryota

126

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

University of Tsukuba Tohoku University The University of Osaka Kyoto University Tokyo Metropolitan Komagome Hospital

About

Ryota Tanaka is an author at University of Tsukuba specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	21	810
2	Cell Biology	6	6	278
3	Allergy	1	1	33
4	Endocrinology	1	1	47
5	Head And Neck Surgery	1	1	12

Ryota Tanaka

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi‐institutional retrospective study Yasuhiro Nakamura, Ryota Tanaka, Yuri Asami, The Journal of Dermatology	2016	220
PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth Mami Morita, Taku Sato, Miyuki Nomura, Cancer Cell Tumor BiologyCell RegulationMedicineCancer BiologyMetabolic Remodeling	2018	173
Intratumoral expression levels of <i>PD-L1</i>, <i>GZMA</i>, and <i>HLA-A</i> along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma Hiroyuki Inoue, Jae‐Hyun Park, Kazuma Kiyotani, OncoImmunology	2016	128
Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies Yoshiyuki Nakamura, Ryota Tanaka, Hiroshi Maruyama, Japanese Journal of Clinical Oncology	2018	112
Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Journal of Dermatological Science Routine Blood CountCancer ImmunosurveillanceOncologyAutoimmune DiseaseMalignant Blood Disorder	2017	101
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study Taku Fujimura, Yota Sato, Kayo Tanita, Oncotarget	2018	88
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain–Barré syndrome: a case report Ryota Tanaka, Hiroshi Maruyama, Yasushi Tomidokoro, Japanese Journal of Clinical Oncology	2016	80
Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma Yuki Honda, Atsushi Otsuka, Sachiko Ono, OncoImmunology	2016	70
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Journal of Dermatological Science Retrospective StudyOncologyMelanomaImmune Checkpoint InhibitorAdvanced Melanoma Patients	2017	66
Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab Ryota Tanaka, Yasuhiro Fujisawa, Sae Inoue, Japanese Journal of Clinical Oncology Melanoma TreatmentImmunologySevere HepatitisPharmacotherapyLiver Function	2016	56

Page 1